Pyxis Oncology (PYXS) Other Gross PP&E Adjustments (2020 - 2025)
Pyxis Oncology (PYXS) reported Other Gross PP&E Adjustments of $2.8 million for Q4 2025, up 10.6% year-over-year from $2.5 million in Q4 2024, and up 123.85% on a QoQ basis from -$11.6 million in Q3 2025.
Pyxis Oncology (PYXS) has 6 years of Other Gross PP&E Adjustments data on file, last reported at $2.8 million in Q4 2025.
- Quarterly Other Gross PP&E Adjustments rose 10.6% year-over-year to $2.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.8 million (up 10.6% YoY) and the FY2025 annual result came in at $2.8 million, up 10.6% from the prior year.
- Other Gross PP&E Adjustments climbed to $2.8 million in Q4 2025 per PYXS's latest filing, from -$11.6 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $2.8 million in Q4 2025 and bottomed at -$15.0 million in Q2 2022.
- The 5-year median for Other Gross PP&E Adjustments is -$11.8 million (2025), against an average of -$7.5 million.
- The widest annual swing landed in 2022, when Other Gross PP&E Adjustments tumbled 3687.63%; it then surged 171.9% in 2023.
- Tracing PYXS's Other Gross PP&E Adjustments over 5 years: stood at $909000.0 in 2021, then sank by 364.69% to -$2.4 million in 2022, then soared by 171.9% to $1.7 million in 2023, then jumped by 45.09% to $2.5 million in 2024, then climbed by 10.6% to $2.8 million in 2025.
- Per Business Quant, the three latest PYXS Other Gross PP&E Adjustments figures stand at $2.8 million (Q4 2025), -$11.6 million (Q3 2025), and -$11.8 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Pyxis Oncology | 120.87 Mn | 103.97 Mn | 8.65 Mn | 2.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.78 Mn |
| Dec 31, 2025 | 2.78 Mn |
| Sep 30, 2025 | -11.64 Mn |
| Sep 30, 2025 | -11.64 Mn |
| Jun 30, 2025 | -11.85 Mn |
| Jun 30, 2025 | -11.85 Mn |
| Mar 31, 2025 | -12.05 Mn |
| Mar 31, 2025 | -12.05 Mn |
| Dec 31, 2024 | 2.51 Mn |
| Dec 31, 2024 | 2.51 Mn |
| Mar 31, 2024 | -12.78 Mn |
| Mar 31, 2024 | -12.78 Mn |
| Dec 31, 2023 | 1.73 Mn |
| Dec 31, 2023 | 1.73 Mn |
| Sep 30, 2023 | -13.13 Mn |
| Sep 30, 2023 | -13.13 Mn |
| Jun 30, 2023 | -13.28 Mn |
| Jun 30, 2023 | -13.28 Mn |
| Mar 31, 2023 | -13.46 Mn |
| Mar 31, 2023 | -13.46 Mn |
| Dec 31, 2022 | -2.41 Mn |
| Dec 31, 2022 | -2.41 Mn |
| Sep 30, 2022 | -14.70 Mn |
| Sep 30, 2022 | -14.70 Mn |
| Jun 30, 2022 | -15.00 Mn |
| Jun 30, 2022 | -15.00 Mn |
| Dec 31, 2021 | 909,000.00 |
| Dec 31, 2021 | 909,000.00 |
| Sep 30, 2021 | -388,000.00 |
| Sep 30, 2021 | -388,000.00 |
| Dec 31, 2020 | 569,000.00 |
| Dec 31, 2020 | 569,000.00 |